Severe gastritis due to pembrolizumab treatment in a lung cancer patient
© 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology..
Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T-lymphocyte antigen-4 (CTLA-4) resembles inflammatory bowel disease (IBD) and that programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Respirology case reports - 8(2020), 7 vom: 05. Okt., Seite e00636 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hayama, Noriko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 16.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/rcr2.636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341233633 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341233633 | ||
| 003 | DE-627 | ||
| 005 | 20231226011317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rcr2.636 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341233633 | ||
| 035 | |a (NLM)35600796 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hayama, Noriko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe gastritis due to pembrolizumab treatment in a lung cancer patient |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. | ||
| 520 | |a Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T-lymphocyte antigen-4 (CTLA-4) resembles inflammatory bowel disease (IBD) and that programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Gastritis | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a immune‐related adverse events | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a pembrolizumab | |
| 700 | 1 | |a Ihara, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Honma, Yuichirou |e verfasserin |4 aut | |
| 700 | 1 | |a Itoigawa, Yukinari |e verfasserin |4 aut | |
| 700 | 1 | |a Kaira, Kyoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Mitsuhiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology case reports |d 2013 |g 8(2020), 7 vom: 05. Okt., Seite e00636 |w (DE-627)NLM244269440 |x 2051-3380 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:7 |g day:05 |g month:10 |g pages:e00636 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rcr2.636 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 7 |b 05 |c 10 |h e00636 | ||